Drug Development/Existing Targets: Develop disease-modifying interventions for LBD based on discovering biomarkers, molecular targets, and genetic and environmental modifiers that enhance, delay, or prevent the onset of disease

Please note: This milestone was incorporated into Milestone 5-D in 2019. Please check Milestone 5-D for updates.

Develop disease-modifying interventions for LBD based on discovering biomarkers, molecular targets, and genetic and environmental modifiers that enhance, delay, or prevent the onset of disease.

2033 RFA-NS-18-107: Planning Grant to Develop Phase III Clinical Trials for Lewy Body Dementia (R34) 5.E In Progress Develop disease-modifying interventions for LBD based on discovering biomarkers, molecular targets, and genetic and environmental modifiers that enhance, delay or prevent the onset of disease. DN 2016 ADRD Summit: Lewy Body Dementias (LBD) Focus Area 4: Model Disease Processes to Develop Potential Symptomatic and Disease Modifying Therapies, Recommendation 8 (PDF, 901K) Drug Development - Existing Targets

• Initiate one or more clinical trials that test prospective therapies based on pharmaceutical approaches, gene therapy, regenerative medicine, surgical interventions, or non-pharmacological approaches to prevent or alter disease processes.